Is Cocrystal Pharma, Inc. (COCP) a Buy, Sell, or Hold?
Cocrystal Pharma, Inc.
NASDAQ:COCP
$0.96 USD
$0.02 (2.1%)
- Volume
- 32.36K
- Average Volume
- 121.42K
- Market Capitalization
- $9.84M
- P/E Ratio
- -1.30
- Dividend Yield
- 0.00%
- Price Target
- $
- Year High
- $2.67
- Year Low
- $0.86
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $2.66
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | James E. Sapirstein |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | COCP |
| CUSIP | 19188J409 |
| CIK | 0001412486 |
| Web | https://www.cocrystalpharma.com |
| Phone | 786 459 1831 |
| Currency | USD |
| Employees | 10 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.35 |
| Payout Ratio | 0.00 |
| Current Ratio | 2.66 |
| Quick Ratio | 2.66 |
| Cash Ratio | 2.10 |
Sales & Book Value
| Annual Sales | $- |
| Price / Sales | 43.73 |
| Cash Flow | -0.57 |
| Price / Cash Flow | -1.26 |
| Price / Book | 3.22 |
Price Target and Rating
| Average Stock Price Forecast | $ |
| High Stock Price Forecast | $ |
| Low Stock Price Forecast | $ |
| Forecast Upside/Downside | % |
| Consensus Rating | Sell |
| Rating Score(0-5) | 2 |
| Research Coverage | 1 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-0.78 |
| Trailing P/E Ratio | -1.30 |
| PEG Ratio | -0.02 |
| P/E Growth | -0.02 |
| Net Income | $-8.83M |
| Net Margin | -3924.00% |
| Pretax Margin | -3924.00% |
| Return on Equity | -150.61% |
| Return on Assets | -118.89% |
Financials Score
| AltmanZ Score | -66.50 |
| Piotroski Score | 3.00 |
| Working Capital | 3.71M |
| Total Assets | 7.43M |
| Ebit | -8.83M |
| Market Cap | 9.64M |
| Total Liabilities | 3.31M |
Poll Results
About Cocrystal Pharma, Inc. (NASDAQ:COCP) Stock
Cocrystal Pharma, Inc. (COCP) is a biotechnology firm dedicated to researching and advancing antiviral treatments for severe and/or persistent viral illnesses. The company leverages structure-based technologies to create new antiviral medications, primarily focusing on infections caused by the hepatitis C virus (HCV), influenza, coronaviruses, and noroviruses. Its current pipeline includes CC-31244, a non-nucleoside polymerase inhibitor for HCV, which has successfully completed Phase IIa clinical trials. Additionally, CC-42344, a PB2 inhibitor designed to combat influenza, is currently undergoing preclinical development. Cocrystal Pharma is also actively pursuing the development of non-nucleoside polymerase inhibitors to address norovirus infections. The company maintains strategic allianc ... es, including a research and licensing collaboration with Merck Sharp & Dohme Corp. for the discovery and development of proprietary influenza A/B antiviral agents. It also holds a licensing agreement with the Kansas State University Research Foundation, aimed at advancing antiviral compounds for norovirus and coronavirus infections. Furthermore, Cocrystal Pharma engages in drug discovery collaborations with both HitGen and InterX Inc. The company's operations are headquartered in Bothell, Washington.
2026-06-03 07:00:00
BOTHELL, Wash. , June 03, 2026 (GLOBE NEWSWIRE) -- Cocrystal Pharma Inc. (Nasdaq: COCP) ("Cocrystal" or the "Company"), a clinical-stage biotechnology company developing novel therapeutics to meet the growing need for effective, safe antiviral treatments, has appointed James Sapirstein Chief Executive Officer, effective immediately.
2026-06-03 07:00:00
BOTHELL, Wash., June 03, 2026 (GLOBE NEWSWIRE) -- Cocrystal Pharma Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”), a clinical-stage biotechnology company developing novel therapeutics to meet the growing need for effective, safe antiviral treatments, has appointed James Sapirstein Chief Executive Officer, effective immediately. The Company also plans to appoint Mr. Sapirstein as a member of the Board of Directors. He has extensive pharmaceutical industry leadership and development experience. Mr. Sapirstein replaces Sam Lee and Jim Martin, who served as Co-Chief Executive Officers. Sam Lee will continue as President and transition to Chief Scientific Officer, and Jim Martin will continue as Chief Financial Officer.
2026-05-26 08:00:00
Novel, potent pan-viral inhibitors targeting the viral replication complex are under development for the treatment of hantavirus, bunyavirus and influenza Hantavirus and bunyavirus infections represent significant unmet medical needs, contribute to ongoing global outbreaks and have no approved treatments or vaccines BOTHELL, Wash., May 26, 2026 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces that its novel direct-acting antivirals demonstrate pan-viral activity against multiple viruses, including hantavirus, bunyavirus and influenza.
Cocrystal Pharma Provides Business Update and Reports First Quarter 2026 Financial Results
2026-05-15 08:00:00
BOTHELL, Wash., May 15, 2026 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) provides updates on its antiviral product pipeline and business activities and reports financial results for the three months ended March 31, 2026.
2026-04-30 16:05:00
BOTHELL, Wash., April 30, 2026 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces that the mechanism of action and clinical advancement of its first oral protease inhibitor CDI-988 were featured today in an oral presentation at the 39th International Conference on Antiviral Research (ICAR 2026) in Prague, Czech Republic. The presentation, titled “First Oral Direct-Acting Antiviral CDI-988 for Norovirus Infection Prevention and Treatment: Novel Mechanism of Action and Phase 1 Study Results,” was delivered by Sam Lee, Ph.D., President and co-CEO of Cocrystal. Presentation slides are available on the Company's website here.
Frequently Asked Questions
-
What is the current Cocrystal Pharma, Inc. (COCP) stock price?
-
Cocrystal Pharma, Inc.(NASDAQ:COCP) stock price is $0.96 in the last trading session. During the trading session, COCP stock reached the peak price of $2.67 while $0.86 was the lowest point it dropped to. The percentage change in COCP stock occurred in the recent session was 2.1% while the dollar amount for the price change in COCP stock was $0.02.
-
COCP's industry and sector of operation?
-
The NASDAQ listed COCP is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of COCP?
-
Sam Lee | Chief Scientific Officer, Co-Founder & President
James R. Sapirstein | Chief Executive Officer
James J. Martin | CFO & Corporate Secretary
Roger D. Kornberg | Co-Founder, Independent Chairman, Chief Scientist & Chairman of Scientific Advisory Board
| -
How many employees does COCP have?
-
Number of COCP employees currently stands at 10. COCP operates from 19805 North Creek Parkway, Bothell, WA 98011, US.
-
Link for COCP official website?
-
Official Website of COCP is: https://www.cocrystalpharma.com
-
How do I contact COCP?
-
COCP could be contacted at phone #786 459 1831 and can also be accessed through its website. COCP operates from 19805 North Creek Parkway, Bothell, WA 98011, US.
-
How many shares of COCP are traded daily?
-
The average number of COCP shares traded daily for last 3 months was 121.42K.
-
What is the market cap of COCP currently?
-
The market value of COCP currently stands at $9.84M with its latest stock price at $0.96